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Abstract
Background:  Bruton's tyrosine kinase (Btk) is essential for B cell development and function.
Mutations of Btk elicit X-linked agammaglobulinemia in humans and X-linked immunodeficiency in
the mouse. Btk has been proposed to participate in B cell antigen receptor-induced signaling events
leading to activation of phospholipase C-γ2 (PLCγ2) and calcium mobilization. However it is unclear
whether Btk activation is alone sufficient for these signaling events, and whether Btk can activate
additional pathways that do not involve PLCγ2. To address such issues we have generated Btk:ER,
a conditionally active form of the kinase, and expressed it in the PLCγ2-deficient DT40 B cell line.
Results:  Activation of Btk:ER was sufficient to induce multiple B cell signaling pathways in PLCγ2-
sufficient DT40 cells. These included tyrosine phosphorylation of PLCγ2, mobilization of
intracellular calcium, activation of extracellular signal-regulated kinase (ERK) and c-Jun NH2-
terminal kinase (JNK) mitogen-activated protein kinase (MAPK) pathways, and apoptosis. In DT40
B cells deficient for PLCγ2, Btk:ER activation failed to induce the signaling events described above
with the consequence that the cells failed to undergo apoptosis.
Conclusions:  These data suggest that Btk:ER regulates downstream signaling pathways primarily
via PLCγ2 in B cells. While it is not known whether activated Btk:ER precisely mimics activated Btk,
this conditional system will likely facilitate the dissection of the role of Btk and its family members
in a variety of biological processes in many different cell types.
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Mutations in Bruton's tyrosine kinase (Btk) are respon-
sible for the human disease termed X-linked agamma-
globulinemia (XLA) (reviewed in reference [1]). The B
cell antigen receptor (BCR) signaling defect is very se-
vere such that XLA patients have a block in the pro-B to
pre-B cell transition and consequently have no mature B
cells. The xid mouse, in which Btk is mutated, and the
Btk knockout mouse display similar, although somewhat
less severe, phenotypes [1]. Btk is the prototypical mem-
ber of the Tec family of non-receptor protein tyrosine ki-
nases (PTKs) that includes Bmx, Itk, Tec and Txk [2, 3].
In addition to a COOH-terminal PTK domain, Btk has an
NH2- terminal pleckstrin homology (PH) domain, a pro-
line-rich Tec homology domain, a Src-homology 3 (SH3)
domain and a Src-homology 2 (SH2) domain. Btk was
originally identified in B cells but is now known to be ex-
pressed in most leukocytes with the exception of T cells
and NK cells.
Btk is thought to be activated upon BCR cross-linking by
a two-step mechanism involving phosphatidylinositol
(PI) 3-kinase and the Src family PTK Lyn (reviewed in
references [4,5,6]). PI 3-kinase induces Btk membrane
targeting by generating phosphatidylinositol 3,4,5-tri-
sphosphate (PIP3) to which the PH domain of Btk binds.
Lyn transphosphorylates Btk within the activation loop
of the kinase domain, allowing subsequent autophos-
phorylation of the Btk SH3 domain and full Btk activa-
tion. The SH2 domain-containing inositol phosphatase
(SHIP) downregulates Btk by dephosphorylating PIP3
[4,5,6].
Biochemical studies of Btk-deficient B cells have shown
Btk to be necessary for BCR-induced phospholipase C-γ2
(PLCγ2) phosphorylation, calcium mobilization, extra-
cellular signal-regulated kinase (ERK) and c-Jun NH2-
terminal kinase (JNK) mitogen-activated protein kinase
(MAPK) activation, NF-κB activation and apoptosis
[7,8,9,10,11,12]. These signaling events are generally not
entirely abrogated and kinetic analyses have revealed
that the sustained phases are particularly impaired in the
absence of Btk [8, 9, 13]. In contrast, these pathways are
completely inhibited in the absence of the Syk/ZAP-70
family tyrosine kinase Syk [14]. These data have led to
the hypothesis that Btk co-operates with Syk in PLCγ2-
dependent BCR signaling and that Btk functions as a sig-
nal duration modulator (reviewed in references [15, 16]).
However, it is not clear if Btk alone is sufficient to mimic
aspects of BCR signaling, nor is it known whether all
downstream signals mediated by Btk are PLCγ2-depend-
ent. Indeed, additional functions for Btk have recently
been proposed, namely in PI 3-kinase activation [17], cy-
toskeletal reorganization [18] and DNA transcription
[19,20,21].
In this study we have generated a conditional form of Btk
by fusing the full length Btk protein with the hormone-
binding domain of the estrogen receptor (Btk:ER). We
show that Btk:ER activation alone is sufficient to activate
multiple downstream signaling pathways in B cells, in-
cluding calcium mobilization, ERK and JNK MAPK, and
apoptosis. Moreover, by analysing Btk:ER function in
PLCγ2-deficient cells, we show that PLCγ2 is necessary
for Btk:ER to transmit these signals.
Results and Discussion
Construction of Btk:ER, a conditional form of Btk
In order to determine whether Btk activation alone is
sufficient to mimic aspects of BCR signaling, we have
generated Btk:ER, a novel conditional form of Btk.
Btk:ER was constructed such that the hormone-binding
domain of the estrogen receptor was fused to the COOH-
terminus of full length Btk (Fig 1A). This approach has
been successful in producing conditional forms of the
Tec family PTK Bmx [22], and also the PTKs v-Src [23],
Hck [24] and Abl [25], the serine/threonine kinases Raf
[26] and Akt [27], and the dual specificity protein kinase
MEK1 [23]. The mechanism of action of ER fusion pro-
teins is not clear, although it appears that upon treat-
ment of cells with estrogen or an estrogen analogue, for
example 4-hydroxytamoxifen (4-HT), the biological ac-
tivities of the proteins are induced. This may involve ER
domain dimerization and/or selective stabilization of ex-
pression within the cell [26]. The ER fusion protein
method has been shown to accurately identify down-
stream substrates and effects of the above mentioned ki-
nases.
Two forms of Btk:ER were generated, one using wild-
type (WT) Btk and the other using a kinase-inactive
(K430E) mutant of Btk as a negative control (Fig 1A).
The Btk:ER constructs were transfected into Btk-defi-
cient DT40 chicken B cells and stable clones were select-
ed that expressed equivalent levels of Btk:ER. The DT40
cell system was used because it has proved useful in dis-
secting B cell signaling pathways through the use of gene
knockouts derived by homologous recombination [15].
Fig 1B shows that WT Btk:ER was kinase active in vitro
as determined by autophosphorylation and phosphor-
ylation of an exogenous substrate (GST-Igα) in an im-
mune-complex kinase assay. Kinase activity was not
detectable for the K430E mutant of Btk:ER (Fig 1B),
comparable to control immunoprecipitations from Btk-
deficient cells (data not shown). In order to determine if
Btk:ER was active in vivo, cells were treated with vehicle
control, 4-HT or anti-µ, and the phosphorylation status
of cellular proteins and Btk:ER were analysed by West-
ern blotting (Fig 1C). Upon 4-HT treatment, a discrete
set of cellular proteins were inducibly phosphorylated in
WT Btk:ER-expressing cells, although their phosphor-
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ed were reduced in comparison with BCR cross-linking.
As a control, 4-HT treatment did not induce phosphor-
ylation of cellular proteins in parental DT40 cells with-
out Btk:ER (data not shown). Btk:ER itself was inducibly
phosphorylated upon 4-HT treatment, as measured by
anti-phosphotyrosine blotting and by a phosphospecific
antiserum that recognises the Y223 site of Btk autophos-
phorylation. Surprisingly, the phosphospecific antise-
rum did not detect Btk:ER Y223 phosphorylation in
response to BCR cross-linking, suggesting that the ob-
served phosphorylation in this case is largely due to the
Y551 Lyn transphosphorylation site. In cells expressing
kinase inactive Btk:ER, phosphorylation of Btk:ER was
not detected and cellular substrates were not inducibly
phosphorylated in response to 4-HT (Fig 1C). These data
suggest that WT Btk:ER, but not the kinase inactive
form, can be activated in vivo by 4-HT. The mechanism
Figure 1
Expression of Btk:ER, a conditional form of Btk, in Btk-deficient DT40 cells. A, Diagrammatic representation of Btk:ER con-
structs. WT and kinase inactive (K430E) forms of Btk were fused at their COOH-terminus to the hormone-binding domain of
the estrogen receptor (ER). B, Immune-complex kinase assay and Western blot analyses of Btk:ER constructs. Btk-deficient
DT40 cells were stably transfected with WT Btk:ER or K430E Btk:ER and clones selected that expressed equal levels of
Btk:ER. Cells were lysed and Btk:ER was immunoprecipitated with specific Btk antiserum. Immune complex kinase assays were
performed using GST-Igα as an exogenous substrate (top panel), in addition to immunoblotting with antisera specific for Btk
(middle panel) and ER (lower panel). C, Activation of Btk:ER in vivo by 4-HT. Cells expressing either WT or kinase inactive
Btk:ER were stimulated with vehicle control, 4-HT (1 µM for 30-min) or anti-µmAb M4 (4 µg/ml for 1-min). Cells were lysed
and Btk:ER was immunoprecipitated with specific Btk antiserum. Whole cell lysates were blotted with mAb 4G10 (top panel).
Btk mmunoprecipitates were blotted with mAb 4G10, phosphospecific Btk Y223 antiserum, or Btk antiserum (lower panels).
PH SH3 SH2 Kinase ER
WT Btk:ER
Kinase inactive Btk:ER
SH3 SH2 Kinase ER
K430E
TH
PH TH
A
Btk:ER
GST-
Igα
Btk:ER
Btk:ER
W
T 
B
tk
:E
R
K
43
0E
 B
tk
:E
R
250
98
64
50
36
30
Btk i.p.
Immune-
complex
kinase
assay
Btk i.p.
Btk blot
Btk i.p.
ER blot
B
WCL
APT blot
Btk:ER115
208
79
50
Ve
hi
cl
e
4-
H
T
A
nt
i-µ
Ve
hi
cl
e
4-
H
T
A
nt
i-µ
W
T 
B
tk
:E
R
K
43
0E
 B
tk
:E
R
Btk i.p.
Btk blot
115
Btk i.p.
pY223 blot
115
Btk i.p.
APT blot
115
C
BMC Immunology (2001) 2:4 http://www.biomedcentral.com/1471-2172/2/4by which 4-HT activates Btk:ER is not known, but may
be different to the mechanism of BCR-induced activa-
tion, since the two stimuli induce phosphorylation on
different sites.
The identity of the cellular proteins phosphorylated
downstream of Btk:ER activation (50-79 kD range, top
panel, Fig 1C) are not known. These proteins are unlikely
to include Lyn or Syk, the two PTKs that are primarily re-
sponsible for the BCR-induced tyrosine phosphorylation
pattern seen in DT40 whole cell lysates [14], since we
were unable to detect phosphorylation of Lyn and Syk
following specific immunoprecipitations (data not
shown). Moreover, the relatively weak phosphorylation
of cellular proteins induced by Btk:ER does not suggest
that Lyn and/or Syk are becoming activated (Fig 1C).
This is consistent with the idea that Lyn and Syk are up-
stream of Btk activation [28].
Btk:ER is sufficient to activate the PLCγ2/calcium pathway
Btk-deficient B cells are defective in BCR-induced PLCγ2
phosphorylation and calcium mobilization [8, 11]. In
particular, the sustained PLCγ2/calcium responses are
impaired. A model has been proposed in which Btk con-
trols calcium influx across the cell membrane by modu-
lating PLCγ2 activity and thus IP3 levels [6, 29]. Here we
tested whether Btk:ER activation was sufficient to acti-
vate the PLCγ2/calcium pathway.
Btk-deficient cells expressing either WT or kinase inac-
tive Btk:ER were treated with 4-HT or anti-µ and PLCγ2
phosphorylation was analysed by Western blotting (Fig
2A). Upon treatment with 4-HT, a sustained PLCγ2
phosphorylation was induced in cells expressing WT
Btk:ER that was not observed in cells expressing kinase
inactive Btk:ER (Fig 2A). As a further control, 4-HT
treatment of Btk-deficient cells, expressing Btk without
the ER domain, did not induce PLCγ2 phosphorylation
(Fig 2B, lanes 9-11). This demonstrates that the 4-HT re-
sponse is specific to Btk:ER. Interestingly, the slow ki-
netics of PLCγ2 phosphorylation in response to Btk:ER
differed markedly from the fast, transient kinetics in re-
sponse to BCR cross-linking (compare Fig 2A, lanes 6-9,
with Fig 2B, lanes 5-8). The slow Btk:ER kinetics are
consistent with data derived from Btk-deficient cells, in
which sustained BCR-induced PLCγ2 phosphorylation,
calcium mobilization and MAPK activation are impaired,
but the initial responses are relatively normal and appear
to be driven by Syk activity (reviewed in reference [15]).
Additionally, the sustained PLCγ2 phosphorylation in-
duced by Btk:ER is in agreement with the idea that Btk
does not activate negative regulatory pathways that turn
off the signal; rather it is Lyn that is thought to be largely
responsible for this aspect of BCR signaling [15].
To determine whether Btk:ER is sufficient to induce a
calcium flux, cells were loaded with indo 1 and the con-
centration of intracellular free calcium monitored by
FACS analysis. Cells were treated with 4-HT and/or anti-
µ as outlined in Fig 2C. Strikingly, upon treatment with
4-HT, WT Btk:ER induced a rapid calcium mobilization
that was at a low level but sustained (Fig 2C). This pat-
tern differed from that seen in response to BCR cross-
linking, where an initial large transient increase in intra-
cellular calcium was followed by lower but sustained lev-
els (Fig 2C). These kinetics are similar to those seen for
PLCγ2 phosphorylation (Figs 2A,B), again consistent
with the idea that Btk regulates the sustained phase of
calcium mobilization. No additive or synergistic effect of
both 4-HT and anti-µ was observed (Fig 2C). This data
indicates that Btk:ER activation alone can induce intrac-
ellular calcium mobilization and is consistent with a pre-
vious study that showed cross-linking of a constitutively
membrane associated CD16/Btk chimera to induce a cal-
cium flux [8].
In order to evaluate whether Btk:ER-induced calcium
mobilization was due to calcium release from internal
stores or calcium influx across cell membrane calcium
release activated channels (CRAC), cells were pre-treat-
ed with EGTA to chelate extracellular calcium (Fig 2D;
note change in scale within Fig. 2D and compared with
Fig 2C). In response to anti-µ treatment of cells express-
ing WT Btk:ER, the sustained elevation of intracellular
calcium was completely blocked in the presence of EG-
TA, whereas the initial transient increase was only slight-
ly impaired. Similarly, in response to 4-HT treatment,
the sustained increase in intracellular calcium levels was
abrogated in the absence of extracellular calcium (Fig
2D). This suggests that Btk:ER may induce calcium re-
lease from intracellular stores which subsequently re-
sults in calcium influx across CRAC. Our data is
consistent with that of Fluckiger et al [8], who proposed
that Btk controls BCR-induced calcium signaling by reg-
ulating PLCγ2 activation, IP3 levels and calcium store
depletion.
Fig 2C shows that kinase inactive Btk:ER was unable to
induce a calcium flux, which, in common with the PLCγ2
data (Fig 2A), suggests that kinase activity is required for
Btk:ER function. However, in the context of signaling
through the BCR, we surprisingly found that kinase inac-
tive Btk:ER could reconstitute calcium mobilization in
these Btk-deficient cells (Fig 2C). This was not an arte-
fact of the ER domain, since non-tagged kinase inactive
Btk could also restore BCR-induced calcium flux (data
not shown). In addition, we have found that kinase inac-
tive Btk can reconstitute BCR-induced ERK MAPK acti-
vation, but not PLCγ2 phosphorylation (Tomlinson,
Bolen and Johnston, unpublished data). This suggests
BMC Immunology (2001) 2:4 http://www.biomedcentral.com/1471-2172/2/4that Btk can function independently of catalytic activity,
perhaps as an adapter protein, and that Btk-induced
PLCγ2 phosphorylation is not essential for PLCγ2 activa-
tion. The mechanism may involve stabilization by Btk of
the PLCγ2 complex, or 'signalosome' [30], in an optimal
conformation or subcellular location. Upon BCR stimu-
lation, Btk is thought to be recruited to PLCγ2 via the
adapter protein BLNK, as BLNK can associate with the
SH2 domains of both PLCγ2 [31, 32] and Btk [33]. Mem-
brane localization of this complex is required for PLCγ2
activation [32], but the mechanism by which this is
achieved is presently unknown (reviewed in [34]). It is
conceivable that a Btk PH domain-PIP3 interaction is
important for membrane localization of the complex,
and that this function is independent of Btk kinase activ-
ity. However, it should be noted that reconstitution of
calcium mobilization in Btk-deficient DT40 cells by ki-
nase inactive Btk was not observed in a previous study
[11]. The reason for this discrepancy is not clear, but may
be due to the different mutations that were used to gen-
erate kinase inactive Btk in the two studies. In the
present study we used a K430E mutation; K430 is the in-
variant lysine known to be essential for enzymatic activ-
ity of protein kinases. In the study of Takata and
Kurosaki [11], Btk was rendered catalytically inactive by
an R525Q mutation. Since K430 is located on the small-
Figure 2
Btk:ER activation is sufficient to induce PLCγ2 phosphorylation and calcium mobilization in Btk-deficient DT40 cells. A, Btk:ER-
induced PLCγ2 phosphorylation. Cells expressing either WT or kinase inactive Btk:ER were lysed as a function of the indicated
times (minutes) after addition of 4-HT (1 µM) or BCR cross-linking with anti-µ mAb M4 (4 µg/ml). PLCγ2 was immunoprecipi-
tated with anti-PLCγ2 antiserum and immunoblotted with anti-phosphotyrosine mAb (APT, top panel) and with anti-PLCγ2
antiserum (bottom panel). B, BCR-induced PLCγ2 phosphorylation in Btk-deficient versus Btk-sufficient cells. The experiment
was performed as described for Fig. 2A. Lanes 1-8 show anti-µ-induced PLCγ2 phosphorylation in Btk-deficient DT40 cells and
in Btk-deficent cells expressing mouse Btk, which were described previously [13]. Lanes 9-12 show 4-HT-induced PLCγ2 phos-
phorylation in Btk-deficient cells expressing Btk or Btk:ER. Lanes 13-15 show a Btk blot of whole cell lysates for Btk-deficient
cells, Btk-deficient cells expressing Btk, and Btk-deficient cells expressing Btk:ER. C, Btk:ER-induced calcium mobilization. Intra-
cellular free calcium levels in indo-1-loaded cells were monitored over an 8-min period by FACS. 4-HT (1 µM) and/or anti-µ
mAb M4 (2 µg/ml) were added at the 60 s time point. Relative intracellular calcium levels are shown on the y-axis. D, Sustained
calcium mobilization is dependent on calcium influx. Intracellular calcium levels were monitored as described in panel B, in the
presence or absence of 3 mM EGTA which chelates extracellular calcium. These data are representative of three independent
stable clones.
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BMC Immunology (2001) 2:4 http://www.biomedcentral.com/1471-2172/2/4er, NH2-terminal lobe of the kinase domain, whereas
R525 is part of the larger, COOH-terminal lobe, it is pos-
sible that the two mutations differentially affect the ca-
pacity of kinase inactive Btk to function as an adapter in
the activation of PLCγ2.
Btk:ER is sufficient to activate ERK and JNK MAPK path-
ways
BCR-induced activation of the ERK and JNK MAPK
pathways is impaired in Btk-deficient DT40 cells, but
p38 MAPK activation is unaffected [9]. The precise role
of Btk in the activation of MAPK pathways is not clear,
but these findings suggest that Btk is required for ERK
and JNK activation. We therefore examined whether
Btk:ER is sufficient to induce ERK and JNK activity.
In Fig 3A, Btk-deficient cells that express either WT or
kinase inactive Btk:ER were treated with 4-HT, or PMA
as a positive control, and ERK activity was assessed by
immune complex kinase assay using MBP as an exoge-
nous substrate. In response to 4-HT, WT Btk:ER, but not
the kinase inactive protein, induced ERK activity which
increased over the time period examined (Fig 3A). The
kinetics were somewhat different to those seen with anti-
µ stimulation, where maximal ERK activity is detected
within 5-min and is sustained for up to 120-min [9].
However Btk:ER was clearly able to induce sustained
ERK activity and this, coupled with the findings that in
Btk-deficient cells the sustained response is impaired
[9], suggest that Btk activation may be responsible for
the prolonged ERK activation normally detected follow-
ing BCR cross-linking. Interestingly, kinase inactive
Btk:ER was able to restore ERK activation in the context
of anti-µ stimulation (Fig. 3A, lanes 6 and 12). This effect
of kinase inactive Btk is consistent with the previous cal-
cium data (Fig. 2C), and supports the idea that Btk can
perform a kinase-independent adapter function.
In Fig 3B, JNK activity was measured by Western blot-
ting whole cell lysates with phosphospecific JNK antise-
rum. This antiserum detects phosphorylation of JNK at
sites T183 and Y185, which correlates with JNK activa-
tion. Addition of 4-HT to cells expressing WT Btk:ER in-
duced JNK phosphorylation to a level that was similar to
that seen with anti-µ treatment (Fig 3B, lanes 2-4) or
with both 4-HT and anti-µ (Fig 3B, lane 5). However we
did not detect JNK phosphorylation following 4-HT
treatment of cells expressing kinase inactive Btk:ER (Fig
3B, lanes 8-9). The weak JNK phosphorylation in cells
expressing kinase inactive Btk:ER, in response to anti-µ
or both 4-HT and anti-µ (Fig 3B, lanes 10-11), suggests a
partial adapter function for Btk. The control treatment
with PMA and ionomycin induced JNK phosphorylation
in both cell types (Fig 3B, lanes 6 and 12). From these
data we conclude that Btk:ER is sufficient to activate the
JNK pathway in B cells.
Btk:ER is sufficient to induce DT40 cell apoptosis
A major biological response of B cells to BCR cross-link-
ing is apoptosis, a function that is strongly induced in
DT40 cells. The mechanism of apoptosis induction is not
clear but is dependent on the expression of Btk [12, 13].
We therefore tested whether the conditional form of Btk
alone can induce apoptosis in DT40 cells.
In Fig 3C, Btk-deficient cells expressing either WT or ki-
nase inactive Btk:ER were treated with 4-HT and/or
anti-µ for 24 hours. Apoptosis was quantitatively meas-
ured by the TUNEL assay, which detects double stranded
DNA breaks that are a hallmark of apoptosis. Remarka-
bly, WT Btk:ER induced apoptosis to a similar extent to
that seen with BCR cross-linking (Fig 3C), despite the
fact that PLCγ2 phosphorylation, calcium mobilization,
ERK and JNK were relatively weakly activated (Figs 2,
3A,B). However, it is clear that the amplitude and dura-
tion of signaling responses can control differential acti-
vation of transcription factors. For example, in B cells,
NF-κB is activated by a large, transient calcium flux,
whereas NFAT is activated by a low, sustained calcium
plateau [35]. Thus in DT40 cells, BCR-induced apoptosis
may be largely controlled by transcription factors that
are themselves activated by low, sustained signals, which
the BCR and Btk:ER can activate equivalently.
A functional kinase domain was required for Btk:ER-in-
duced apoptosis, as kinase inactive Btk:ER failed to in-
duce apoptosis in response to either 4-HT or anti-µ
stimulation (Fig 3C). Interestingly, a low level of apopto-
sis was observed in response to both 4-HT and anti-µ in
cells expressing kinase inactive Btk:ER (Fig 3C). This
again suggests an adapter function for kinase inactive
Btk which here was facilitated by 4-HT. The PMA and
ionomycin control induced apoptosis in both cell types
(data not shown).
Btk:ER-induced calcium mobilization, ERK and JNK activa-
tion, and apoptosis are dependent on PLCγ2
Biochemical analyses of Btk-deficient cells have suggest-
ed that PLCγ2 is a downstream substrate of Btk [8, 11].
However, the importance of PLCγ2 in Btk signaling has
not been explored. In particular, it is not clear if the ca-
pacity of Btk to connect to downstream signaling path-
ways, such as calcium mobilization, MAPK activation
and apoptosis, is mediated through PLCγ2 or whether it
can occur via other pathways. In particular, recent re-
ports have suggested that in addition to PLCγ2 activa-
tion, Btk may function in PI 3-kinase activation,
cytoskeletal reorganization and DNA transcription. Btk
was shown to be required for normal phosphorylation of
BMC Immunology (2001) 2:4 http://www.biomedcentral.com/1471-2172/2/4Figure 3
Btk:ER activation is sufficient to induce ERK and JNK activation, and apoptosis, in Btk-deficient DT40 cells. A, Btk:ER-induced
ERK MAPK activation. Cells were lysed as a function of the indicated times (minutes) after addition of 4-HT (1 µM), anti-µ
mAb M4 (4 µg/ml), or phorbol 12-myristate 13-acetate (PMA, 100 ng/ml) as a positive control. ERK1 and ERK2 were immuno-
precipitated with ERK1 and ERK2 antisera. Immune complex kinase assays were performed using myelin basic protein as an
exogenous substrate (top panel). Samples were immunoblotted with anti-ERK1 and ERK2 antisera to show equal loading (bot-
tom panel). ERK1 and ERK2 were not resolved as individual bands in these experiments, and ERK2 was the major species
detected (data not shown). B, Btk:ER-induced JNK phosphorylation. Cells were lysed as a function of the indicated times (min-
utes) after addition of 4-HT (1 µM) and/or anti-µ mAb M4 (4 µg/ml), or PMA (100 ng/ml) and ionomycin (250 ng/ml) as a pos-
itive control. Whole cell lysates were immunoblotted with anti-active JNK phosphospecific antiserum. C, Btk:ER-induced
apoptosis. Cells expressing either WT or kinase inactive Btk:ER were cultured for 24 h with 4-HT (1 µM) and/or anti-µ mAb
M4 (2 µg/ml). Apoptosis was measured by TUNEL assay. The percentage of TUNEL-positive cells was calculated with refer-
ence to a negative control TUNEL reaction in the absence of terminal transferase. Negative controls yielded less than 1%
TUNEL-positive cells in all cases. These data are representative of at least three independent stable clones.
50
36
30
16
0    10    30    60    15           5                0    10    30    60     15          5
   4-HT           PMA     Anti-µ                    4-HT            PMA    Anti-µ
Erk i.p.
MBP
kinase
assay
Erk i.p.
Erk blot
WT Btk:ER                              K430E Btk:ER
A
1      2      3      4      5          6                 7      8      9     10   11         12
WT Btk:ER                 K430E Btk:ER
pJNK1
B
1     2    3    4    5    6     7    8    9    10  11  12
C
Un
tre
at
ed
4-
H
T 
 3
0'
4-
H
T 
 6
0'
A
nt
i-µ
4-
H
T 
+ 
an
ti-
µ
PM
A
 +
 io
no
m
yc
in
Un
tre
at
ed
4-
H
T 
 3
0'
4-
H
T 
 6
0'
A
nt
i-µ
4-
H
T 
+ 
an
ti-
µ
PM
A
 +
 io
no
m
yc
in
Percentage
apoptotic
cells
A
nti-µ
 +
 4-H
T
A
nti-µ
4-H
T
Unstim
ulated
A
nti-µ
 +
 4-H
T
A
nti-µ
4-H
T
Unstim
ulated
WT Btk:ER                K430E Btk:ER
0
20
40
60
80
BMC Immunology (2001) 2:4 http://www.biomedcentral.com/1471-2172/2/4a novel adapter protein, named BCAP, which couples
BCR-activated PTKs to PI 3-kinase activation [17]. Btk
may also regulate cytoskeletal reorganization by phos-
phorylating the Wiskott-Aldrich syndrome protein
(WASP) [18], which plays a role in actin polymerization.
Finally, Btk has been reported to shuttle to the nucleus
and may function in transcription by binding the tran-
scription factors Bright and BAP-135/TFII-I [19,20,21,
36]. Thus Btk may have multiple targets, and it is not
known which Btk-induced signals are transmitted via
PLCγ2.
To address these questions we have expressed Btk:ER in
parental and PLCγ2-deficient DT40 cells. Parental DT40
cells were considered a better control than the Btk-defi-
cient cells used previously (Figs 1-3), as both PLCγ2-de-
ficient and parental cells express endogenous chicken
Btk. Thus parental and PLCγ2-deficient cells were trans-
fected with kinase active Btk:ER and stable clones select-
ed that expressed equivalent levels of Btk:ER, as
measured by anti-Btk Western blotting of whole cell
lysates (Fig 4A).
To test whether PLCγ2 is required for Btk:ER-induced
calcium mobilization, parental and PLCγ2-deficient cells
expressing Btk:ER were treated with 4-HT and/or anti-
µ, or ionomycin as a positive control (Fig 4B). Btk:ER in-
duced a sustained calcium signal in parental cells but not
in PLCγ2-deficient cells (Fig 4B), suggesting that Btk:ER
modulates calcium signaling by affecting PLCγ2 activity.
Consistent with previous data, no calcium mobilization
was observed in PLCγ2-deficient cells in response to
anti-µ [37], but as expected a calcium flux was detected
in response to ionomycin, that bypasses receptor-proxi-
mal signaling events (Fig 4B). These data argue against
the possibility that Btk:ER directly controls a CRAC. In-
stead, our data are consistent with the model that Btk:ER
indirectly controls calcium signaling by regulating PLCγ2
activity and thus IP3 levels and calcium store depletion
[6, 8, 29].
In Fig 5 we have tested whether PLCγ2 is required for
Btk:ER-induced ERK and JNK activation, and apoptosis.
Two different BCR signaling pathways can result in ERK
activation in DT40 cells, namely a PLCγ2-independent
Grb2/Sos pathway and a PLCγ2-dependent pathway that
requires protein kinase C [38]. In Fig 5A we found that
Btk:ER activated ERK MAPK in parental but not in
PLCγ2-deficient cells (lanes 2 and 7). Thus Btk:ER ap-
pears to induce ERK activation through its capacity to ac-
tivate PLCγ2, and not through a Grb2/Sos pathway. In
response to a 60-min treatment with anti-µ, ERK activa-
tion was detected in parental but not in PLCγ2-deficient
cells (Fig 5A, lanes 3-4 and 8-9), but control PMA treat-
ment activated ERK in both cell types (Fig 5A, lanes 5
and 10). Transient ERK activation, 5 to 10-min after anti-
µ treatment, can be detected in PLCγ2-deficient cells
[13]. These kinetics are identical to those observed in
Btk-deficient cells [13]. Together with our Btk:ER data,
this suggests that Btk:ER controls sustained ERK activa-
tion in B cells by regulating PLCγ2 activity.
The mechanism by which Btk connects to the JNK path-
way is not clear. One possibility is that Btk can directly
Figure 4
Btk:ER-induced calcium mobilization is dependent on PLCγ2. A, expression of Btk:ER in parental and PLCγ2-deficient DT40
cells. WT Btk:ER was transfected into parental and PLCγ2-deficient cells and stable clones selected that expressed equal levels
of Btk:ER. Whole cell lysates were immunoblotted with antiserum specific for Btk. B, Btk:ER-induced calcium mobilization is
dependent on PLCγ2. Calcium mobilization in parental and PLCγ2-deficient cells expressing Btk:ER was measured as described
in the legend for Fig 2C. Ionomycin (250 ng/ml) was used as a positive control.
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Btk:ER-induced ERK and JNK activation, and apoptosis, are dependent on PLCγ2. A, Btk:ER-induced ERK MAPK activation is
dependent on PLCγ2. Parental and PLCγ2-deficient cells expressing Btk:ER were treated for 60-min with vehicle control (0.1%
ethanol), 4-HT (1 µM) and/or anti-µ mAb M4 (4 µg/ml), or for 15-min with PMA (100 ng/ml) as a positive control. ERK activa-
tion was measured by immune complex kinase assay as described in the legend for Fig 3A. B, Btk:ER-induced JNK phosphoryla-
tion is dependent on PLCγ2. Parental and PLCγ2-deficient cells expressing Btk:ER were treated for 30-min with vehicle control
(0.1% ethanol), 4-HT (1 µM) and/or anti-µ mAb M4 (4 µg/ml), or for 10-min with PMA (100 ng/ml) and ionomycin (250 ng/ml)
as a positive control. JNK phosphorylation was measured by immunblotting with anti-active JNK phosphospecific antiserum as
described in the legend for Fig 3B. C, Btk:ER-induced apoptosis is dependent on PLCγ2. Apoptosis of parental and PLCγ2-defi-
cient cells expressing Btk:ER was measured by TUNEL assay as described in the legend for Fig 3C. PMA (100 ng/ml) and iono-
mycin (250 ng/ml) were used as a positive control. These data are representative of three independent stable clones.
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cascade. This pathway is controlled by the small GTP-
binding protein Rac1 and in DT40 cells Rac1 is essential
for BCR-induced JNK activation [38]. Thus another pos-
sibility is that Btk might directly regulate Rac1 activity.
Alternatively, since the combination of protein kinase C
and calcium signaling is sufficient to activate JNK [9,
38], Btk could activate JNK indirectly through activation
of PLCγ2. In Fig 5B we show that Btk:ER-mediated JNK
activation is dependent on PLCγ2. Upon 4-HT treat-
ment, phosphorylated JNK was detected in parental cells
but not in PLCγ2-deficient cells (Fig 5B, lanes 2 and 7).
PLCγ2-deficient cells also failed to activate JNK in re-
sponse to anti-µ treatment or a combination of anti-µ
and 4-HT (Fig 5B, lanes 3-4), whereas parental cells did
activate JNK following these treatments (Fig 5B, lanes 8-
9). In response to PMA and ionomycin, activated JNK
was detected in both WT and PLCγ2-deficient cells (Fig
5B, lanes 5 and 10). These data are in agreement with
previous reports that document the requirement for
PLCγ2 in BCR-induced JNK activation [38]. Moreover,
the data suggest that Btk:ER activates JNK by a mecha-
nism that is dependent on PLCγ2, rather than through
activation of more downstream elements of the JNK cas-
cade.
Apoptosis is a major biological response of B cells to BCR
cross-linking and Btk is clearly necessary for this effect in
DT40 cells [12, 13]. Here we have shown Btk:ER activa-
tion to be sufficient to induce apoptosis in DT40 cells
(Fig 3). In Fig 5C we have investigated the mechanism by
measuring Btk:ER-induced apoptosis in parental and
PLCγ2-deficient cells. Twenty-four hours after 4-HT
treatment, apoptosis was detected in WT but not in
PLCγ2-deficient cells (Fig 5C). The response of parental
cells to 4-HT was consistently lower than in response to
anti-µ (Fig 5C and data not shown). This is in contrast to
the Btk-deficient cells analysed earlier (Fig 3), where 4-
HT and anti-µ yielded an equivalent apoptotic response.
This partially impaired function of Btk:ER in parental
cells compared to Btk-deficient cells, in eliciting a biolog-
ical response, may be due to the presence of endogenous
chicken Btk that could compete with Btk:ER for optimal
subcellular location. Apoptosis was not detected above
background levels in PLCγ2-deficient cells that were
treated with anti-µ or both anti-µ and 4-HT (Fig 5C).
This is consistent with reports that PLCγ2 is necessary
for BCR-induced apoptosis [37]. Apoptosis was detected
in parental and PLCγ2-deficient cells in response to the
control PMA and ionomycin treatment (Fig 5C). These
data suggest that Btk:ER induces apoptosis in DT40 B
cells by a PLCγ2-dependent mechanism.
In DT40 B cells, apoptosis induction by Btk:ER may be a
consequence of its capacity to activate JNK, since in
these cells JNK activation correlates more closely with
apoptosis than does ERK activation. In particular, we
have found that Btk-deficient DT40 cells reconstituted
with Txk, an atypical Tec family PTK, fail to undergo
BCR-induced JNK activation (Tomlinson and Johnston,
unpublished data) and apoptosis [13], but ERK activa-
tion is relatively normal [13]. In contrast to the pro-ap-
optotic role for Btk in DT40 cells, Btk appears to play an
anti-apoptotic role in mature B cells in vivo. The mecha-
nism may involve Btk-dependent activation of the tran-
scription factor NF-κ B [7, 10] and subsequent
upregulation of the anti-apoptotic protein Bcl-XL [39,
40].
Previous studies have shown that DT40 cells deficient for
Btk and PLCγ2 have similar BCR signaling defects. Rea-
douts have included calcium mobilization and apoptosis
[11, 37], MAPK activation [9, 38] and NF-κB activation
[41]. In addition, mice deficient for Btk and PLCγ2 have
similar defects in B cell development and function (re-
viewed in [30]). These findings have lead to the hypoth-
esis that Btk and PLCγ2 are components of the same
signaling unit, or signalosome [30]. However, these find-
ings have not proved that Btk connects to the above men-
tioned pathways via PLCγ2. In the present study, while
we cannot rule out the possibility that Btk:ER activates
PLCγ2 in combination with other uncharacterized path-
ways, our data strongly support the Btk/PLCγ2 signalos-
ome model by showing that PLCγ2 is absolutely required
for Btk:ER-induced calcium, MAPK and apoptosis re-
sponses.
Conclusions
The Btk mutations found in XLA patients and the xid
mouse show that Btk is required for normal B cell devel-
opment, but the important pathways activated by Btk
have yet to be fully identified. In this paper we show that
a conditional form of Btk (Btk:ER) is sufficient to acti-
vate many signaling pathways downstream of the anti-
gen receptor, including PLCγ2 phosphorylation, calcium
mobilization, apoptosis and ERK and JNK activation.
Our findings clearly indicate that all of these Btk:ER-me-
diated responses require PLCγ2. In future studies,
Btk:ER may be a useful tool for the identification of Btk
phosphorylation sites on PLCγ2, and for the discovery of
novel substrates.
Materials and methods
Cells
DT40 cells were cultured in RPMI 1640 supplemented
with 10% fetal calf serum, 1% chicken serum (Sigma),
penicillin, streptomycin, glutamine, and 50 µM mercap-
toethanol. DT40 cells rendered deficient for btk and
plcγ2 by homologous recombination were described pre-
viously [11, 37].
BMC Immunology (2001) 2:4 http://www.biomedcentral.com/1471-2172/2/4Antibodies
Anti-chicken µ mAb M4 [14], anti-Btk antiserum [42]
and anti-Btk Y223 phosphospecific antiserum [43] were
as described. Anti-phosphotyrosine mAbs were 5H1 [42]
and 4G10 (Upstate Biotechnology, NY). Antisera against
PLCγ2, ERK1, ERK2 and the hormone-binding domain
of the estrogen receptor (ER) were from Santa Cruz Bio-
technology (Santa Cruz, CA), and anti-active JNK antise-
rum was from Promega (Madison, WI).
Biochemical analyses
Btk:ER proteins were activated with 4-hydroxyta-
moxifen (4-HT; Research Biochemicals International).
Immunoprecipitations, immune complex protein kinase
assays, and immunoblotting were as described previous-
ly [44]. ERK MAPK assays were as described [26]. For
JNK assays, cells were resuspended in RPMI 1640 sup-
plemented with 2.5% fetal calf serum, and following
stimulation whole cell lysates were analysed by Western
blotting with anti-active JNK antiserum.
Cloning and transfection of Btk:ER constructs
Cloning of mouse Btk was as described [42]. Kinase-in-
active (K430E) Btk was generated by a two-step PCR
mutagenesis strategy [42]. To generate Btk:ER, DNA se-
quences encoding full-length mouse Btk were amplified
by PCR from Btk cDNA using the following primers: 5'-
TAGTAGGGATCCAGGAAGCCATGGCTGCAGTG-3' and
5'-TAGTAGGGATCCGCGGATTCTTCATCCATC-3'. The
PCR product was cloned into the BamHI site of pBP3:ER
(pBabepuro containing the hormone-binding domain of
the HE14 allele of the human estrogen receptor) [26].
Btk:ER constructs were subcloned from pBP3:Btk:ER
into the EcoRI site of the pApuroII vector. DT40 cells
were transfected with pApuroII:Btk:ER by electropora-
tion and stable clones selected [14].
Calcium flux analyses
DT40 cells were labeled with 1 µM indo-1 AM (Molecular
Probes, Eugene, OR) for 30-min at room temperature.
After labeling, cells were washed and resuspended in
RPMI 1640 supplemented with 1% fetal calf serum and
20 mM Hepes buffer. In some experiments extracellular
calcium was chelated by pre-treating the cells with 3 mM
EGTA for 15-min. Calcium flux was measured using a
FACSVantage (Becton Dickinson, Mountain View, CA).
Apoptosis assay
DT40 cells were treated for 24 h and flow cytometry
analyses of apoptotic cells was performed using the
TUNEL in situ cell death detection kit (Roche Molecular
Biochemicals). Flow cytometry was performed using a
FACSCalibur (Becton Dickinson) and analyzed using
CellQuest software (Becton Dickinson).
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